KRYS Stock — Krystal Biotech Inc.

Krystal Biotech Inc. (KRYS)

Updated October 16, 2026.

KRYS is a Stock. Total return is 2875.4% over the past 9.1 years, 2625.1 points ahead of SPY at 250.3%.

Krystal Biotech is a commercial-stage biotechnology company that discovers, develops, and commercializes genetic medicines for diseases with high unmet medical needs. The company markets VYJUVEK for dystrophic epidermolysis bullosa and maintains a pipeline of candidates in clinical trials addressing conditions ranging from ocular and skin disorders to cystic fibrosis and cancer. The company does not currently have an established distribution schedule.

KRYS performance versus SPY

Price and return data through 2026-10-16.

Total return is 2875.4% over the past 9.1 years, 2625.1 points ahead of SPY at 250.3%. Over the past year its total return — price change plus distributions reinvested — is 68.1%. Its deepest 1-year drawdown was 17.3%.

KRYS key facts

Asset type

Stock

Asset class

Equity

Inception date

09/20/2017

Distribution frequency

None

Last close

$316.58 (as of 2026-10-16)

Market cap

$9,370,399,501

Average volume

226220.0

Beta

0.498

Payout ratio

0.0%

P/E ratio

38.51

Forward P/E

46.9484

EPS

$8.22

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

KRYS risks and drawbacks

The deepest 1-year drawdown on record here is 17.3%.

Who may consider KRYS — and who may not

It is a weaker fit for investors who need monthly cash flow (KRYS does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on KRYS

• All tickers starting with K

Tagged: Healthcare.

Frequently asked questions